STOCK TITAN

Mesa Labs Acquires Belyntic’s Peptide Purification Business

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Rhea-AI Summary

Mesa Laboratories (NASDAQ: MLAB) announced the acquisition of Belyntic GmbH's peptide purification business assets, excluding current assets. This strategic move aims to enhance Mesa's peptide synthesis offerings and support biopharmaceutical development. The transaction is not expected to materially impact Mesa's ongoing operations. The acquisition introduces Belyntic's Peptide Easy Clean Linker, which improves ecological impact by reducing solvent use in peptide purification. Mesa remains focused on quality control solutions for healthcare and medical device sectors.

Positive
  • Acquisition enhances Mesa's peptide synthesis capabilities.
  • Introduces environmentally friendly Peptide Easy Clean Linker.
  • Strategically aligns with Mesa's focus on the biopharmaceutical market.
Negative
  • None.


Lakewood, Colorado, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“we”, “Mesa” or the “Company”), a global leader in the design and manufacturing of critical quality control solutions for the pharmaceutical, healthcare, and medical device industries, today announced the acquisition of substantially all of the assets (other than current assets) and certain liabilities related to Belyntic GmbH’s (“Belyntic”) peptide purification business. The transaction price and near-term financial impact are not material to Mesa’s ongoing operations.

“The acquisition of Belyntic’s peptide purification products provide Mesa with a natural complement to our peptide synthesis business by adding an advantaged consumables product line. The combination will enhance Mesa’s focus on the biopharmaceutical market to support faster therapeutic development.” said Gary Owens, President and Chief Executive Officer of Mesa. “Belyntic has developed a best-in-class solution for the parallel purification and modification of difficult peptides. Their Peptide Easy Clean (“PEC”) Linker represents the first broadly applicable peptide purification kit that utilizes catch-and-release methodologies, drastically reducing the need for organic solvents, improving the ecological impact.”

About Mesa Laboratories, Inc.

Mesa is a global leader in the design and manufacturing of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world.

Forward Looking Statements

This press release may contain information that constitutes "forward-looking statements." Generally, the words "believe," “will”, “estimate,” "expect," "project," “anticipate,” “intend” and similar expressions identify forward-looking statements, which generally are not historical in nature. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future — including statements relating to revenues growth and statements expressing general views about future operating results — are forward-looking statements. Management believes that these forward-looking statements are reasonable as and when made. However, caution should be taken not to place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our historical experience and present expectations or projections. These risks and uncertainties include, but are not limited to, those described in our Annual Report on Form 10-K for the year ended March 31, 2022, and those described from time to time in our subsequent reports filed with the Securities and Exchange Commission.



FAQ

What acquisition did Mesa Laboratories announce?

Mesa Laboratories announced the acquisition of Belyntic GmbH's peptide purification business assets on November 17, 2022.

How does the acquisition impact Mesa Laboratories?

The acquisition is not expected to materially impact Mesa Laboratories' ongoing operations but enhances its peptide synthesis offerings.

What is the significance of Belyntic's Peptide Easy Clean Linker?

Belyntic's Peptide Easy Clean Linker reduces the need for organic solvents, improving ecological impact and supports peptide purification.

What market does Mesa Laboratories aim to support with this acquisition?

Mesa Laboratories aims to enhance its support for the biopharmaceutical market through this acquisition.

Mesa Laboratories Inc

NASDAQ:MLAB

MLAB Rankings

MLAB Latest News

MLAB Stock Data

565.55M
5.12M
5.79%
91.91%
2.77%
Scientific & Technical Instruments
Industrial Instruments for Measurement, Display, and Control
Link
United States of America
LAKEWOOD